SUCCESSOR-2
Phase 3 Study Evaluating the Safety and Effectiveness of Investigational Drug Mezigdomide in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
What will happen during the trial?
This study is being conducted in two different parts, or stages.
STAGE 1
In Stage 1, there are four planned groups, also called arms. Three of the four arms will receive different dose levels of investigational drug mezigdomide in combination with approved treatments carfilzomib and dexamethasone, and one arm will receive approved treatments carfilzomib and dexamethasone.
STAGE 2
In Stage 2, there are two planned arms. One arm will receive mezigdomide (at the selected dose determined by stage 1), Carfilzomib and Dexamethasone, and the other arm will receive Carfilzomib and Dexamethasone.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 525 patients (estimated)
- Sponsors
- Bristol Myers Squibb
- Tags
- Cereblon E3 Ligase Modulators (CELMoDs), Randomization
- Trial Type
- Treatment
- Last Update
- 5 hours ago
- SparkCures ID
- 1320
- NCT Identifier
- NCT05552976
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.